Posts

BMS Breaks Clinical Losing Streak with Positive Phase 3 Myeloma Readout for Iberdomide

on

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

on

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

on

Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey

on

J&J's Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

on

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

on

Bristol Myers Squibb and Pfizer Launch Direct-to-Consumer Discount Program for Eliquis

on

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

on

Bristol Myers Squibb Hires Goldman Sachs Biotech Analyst Chris Shibutani as Chief Strategy Officer

on

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

on

Bristol Myers Squibb Commits Up to $11B+ in Major BioNTech Solid Tumor Bispecific Antibody Deal

on

Bristol Myers CMO Addresses LAG-3 Concerns After Opdualag's Adjuvant Melanoma Setback at ASCO 2025

on

Bristol Myers Squibb Signs $11B Deal With BioNTech for Bispecific Cancer Antibody BNT327, Surpassing Recent Merck and Pfizer Moves

on

Bristol Myers CEO: America's Biopharma Leadership Not Guaranteed

on

'Now is not the time to retreat': BMS CEO blasts Trump admin tariffs, health reforms amid $40B US investment pledge

on

Over 500 BMS jobs axed in latest round of NJ cuts

on

BMS to close Illinois site as part of cell therapy manufacturing consolidation

on

Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

on

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

on